Modern management of peritoneal carcinomatosis of colorectal origin – Is hyperthermic intraoperative peritoneal chemotherapy the treatment of first choice?

Jagdeep Singh, Thomas Bachleitner-Hofmann, Stefan Riss

Abstract


Although cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is still considered as “experimental” by many, there is growing evidence that supports its general use in selective patients with peritoneal carcinomatosis of colorectal origin.

The selection of patients remains challenging but is the crucial key to achieve optimal oncological results. Recent studies have shown promising results of systemic chemotherapy with biological agents in the treatment of patients with peritoneal carcinomatosis. Thus, the combination of systemic chemotherapy with CRS and HIPEC could even improve overall survival in affected patients. Future studies are required to evaluate the effectiveness of multimodal therapy and to establish a standardized protocol for the treatment of patients with peritoneal carcinomatosis.


Full Text: PDF DOI: 10.5430/jst.v4n2p1

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Journal of Solid Tumors

ISSN 1925-4067(Print)   ISSN 1925-4075(Online)

Copyright © Sciedu Press


To make sure that you can receive messages from us, please add the 'Sciedu.ca' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.